Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development

Questions: Discounts, Updates etc.

Pages: 250

Price (Single): $3995

Price (Company):

Publication Date: 2008-03-01

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *


With their ability to differentiate and become an ongoing source of cells that make up critical tissues and organs, stem cells have potential for new regenerative therapies and as new research tools for drug developers to test emerging therapies on diseased cells.

For market-watchers in the pharmaceutical industry, the question is what potential they have and where they could take the market. Kalorama Information has tackled that question in Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development. Kalorama analyst Alison Sahoo has built models to determine the best, moderate and worst case scenarios for the three key markets for stem cells:

This report breaks down forecasted revenues and procedure volumes for stem cell technologies for these segments in the following disease areas:

Ths report is the result of exclusive interviews with executives in the stem cell industry, a review of medical and company literature, government databases and publications. As part of this comprehensive analysis of stem cell markets, the following companies were profiled:

Table of Contents


EXECUTIVE SUMMARY

INTRODUCTION

 

  • CURRENT STEM CELL THERAPIES
    • Cancer
    • Leukemia
    • Gene Therapy
  • Multiple Myeloma
  • Non-Hodgkin’s Lymphoma
  • Noncancerous Diseases
    • Aplastic Anemia
    • Immunodeficiency
    • Lupus
    • Sickle Cell Disease
    • Other Conditions
  • DEVELOPMENTAL STEM CELL THERAPIES
    • Alzheimer’s Disease
    • Arthritis
    • Burns
    • Cancer
    • Cardiovascular Conditions
    • Critical Limb Ischemia
    • Crohn’s Disease
    • Diabetes
    • Incontinence
    • Infertility
    • Liver Failure
    • Lung Disease
    • Multiple Sclerosis
    • Orthopedics
    • Osteoporosis
    • Parkinson’s Disease
    • Sickle Cell Disease
    • Best Case
      • Stem Cell Therapeutics
      • Fees Related to Drug Development
    • Most Likely Case
      • Stem Cell Therapeutics
      • Fees Related to Drug Development
    • Worst Case
      • Stem Cell Therapeutics
      • Umbilical Cord Blood Banking
      • Fees Related to Drug Development
    • ISSUES IN STEM CELL RESEARCH
      • Ethical Questions
      • Research Funding
        • Federal Funding
        • State Funding
      • International Initiatives
      • Stem Cell Patents
      COMPANY PROFILES
      • Aastrom Biosciences
        • History and Lines of Business
        • Financial Information
        • Stem Cell Technology
      • Advanced Cell Technologies
        • History and Lines of Business
        • Financial Information
        • Stem Cell Technology
      • Brainstorm Cell Therapeutics
        • History and Lines of Business
        • Financial Information
        • Stem Cell Technology
      • Celegene
        • History and Lines of Business
        • Financial Information
        • Stem Cell Technology
      • Cord Blood America
        • History and Lines of Business
        • Financial Information
        • Stem Cell Technology
      • Cord Blood Registry
        • History and Lines of Business
        • Financial Information
        • Stem Cell Technology
      • Cryo-Cell International
        • History and Lines of Business
        • Financial Information
        • Stem Cell Technology
      • ES Cell International
        • History and Lines of Business
        • Financial Information
        • Stem Cell Technology
      • Geron
        • History and Lines of Business
        • Financial Information
        • Stem Cell Technology
      • Harvest Technologies
        • History and Lines of Business
        • Financial Information
        • Stem Cell Technology
      • Invitrogen
        • History and Lines of Business
        • Financial Information
        • Stem Cell Technology
      • Medistem
        • History and Lines of Business
        • Financial Information
        • Stem Cell Technology
      • Neostem
        • History and Lines of Business
        • Financial Information
        • Stem Cell Technology
      • Opexa Therapeutics
        • History and Lines of Business
        • Financial Information
        • Stem Cell Technology
      • Osiris Therapeutics
        • History and Lines of Business
        • Financial Information
        • Stem Cell Technology
      • Plureon
        • History and Lines of Business
        • Financial Information
        • Stem Cell Technology
      • Regenetech
        • History and Lines of Business
        • Financial Information
        • Stem Cell Technology
      • Revivicor
        • History and Lines of Business
        • Financial Information
      • Stem Cell Sciences
        • History and Lines of Business
        • Financial Information
        • Stem Cell Technology
      • StemLifeLine
        • History and Lines of Business
        • Financial Information
        • Stem Cell Technology
      • ThermoGenesis
        • History and Lines of Business
        • Financial Information
        • Stem Cell Technology
      • VetCell Bioscience
        • History and Lines of Business
        • Financial Information
        • Stem Cell Technology
      • ViaCell
        • History and Lines of Business
        • Financial Information
        • Stem Cell Technology

      TABLE OF EXHIBITS

      CHAPTER ONE: EXECUTIVE SUMMARY
      • Table 1-1: Total Market for Stem Cell Technologies in $ Millions, 2007-2020
      • Table 1-2: Stem Cell Therapeutics Market in $ Millions, 2007-2020
      • Table 1-3: Total Market for Cord Blood Banking Fees in $ Millions, 2007-2020
      • Table 1-4: Total Market for Stem Cell Drug Development Technologies in $ Millions, 2007-2020
      CHAPTER THREE: CURRENT STEM CELL THERAPIES
      • Table 3-1: Types of Leukemia, 2007
      CHAPTER FOUR: DEVELOPMENTAL STEM CELL THERAPIES
      • Table 4-1: Global Disease Populations Addressed by Potential Stem Cell Therapies, 2007
      • Table 4-2: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020
      • Table 4-3: Estimated and Projected World Cancer Mortality by Selected Types of Cancer, 2007 and 2020
      • Table 4-4: Types and Features of Urinary Incontinence, 2007vTable 4-5: Types and Causes of Male Infertility, 2007
      • Table 4-6: Common Diseases of the Lungs, 2007
      CHAPTER FIVE: MARKET ANALYSIS
      • Table 5-1: Persons Affected by Key Stem Cell Therapeutic Targets in Millions, 2007
      • Table 5-2: Best Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2007 - 2020
      • Table 5-3: Best Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2007 - 2020
      • Table 5-4: Best Case: Cord Blood Banking Revenues in $ Millions, 2007-2020
      • Table 5-5: Best Case: Stem Cell-Based Drug Development Technology Fees, 2007-2020 (Preclinical Drug Candidates, Cost of Testing, Utilization of New Technology, Cost of New Technolgy per Drug)
      • Table 5-6: Best Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2007-2020
      • Table 5-7: Most Likely Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2007 - 2020
      • Table 5-8: Most Likely Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2007-2020
      • Table 5-9: Most Likely Case: Cord Blood Banking Revenues in $ Millions, 2007-2020
      • Table 5-10: Most Likely Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2007-2020
      • Table 5-11: Most Likely Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2007-2020
      • Table 5-12: Worst Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2007 - 2020
      • Table 5-13: Worst Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2007-2020
      • Table 5-15: Worst Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2007-2020
      • Table 5-16: Worst Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2007-2020
      ISSUES IN STEM CELL RESEARCH
      • Table 6-1: NIH Funding for Stem Cell Research in $ Million, 2003-2008 (est.)
      • Table 6-2: Positions on Human ES Cell Research by Country, 2007
      COMPANY PROFILES
      • Table 7-1: Main Activities of Selected Stem Cell Companies, 2007
      • Table 7-2: Therapeutic Focus of Selected Stem Cell Therapeutics Companies, 2007

    •  

     

    Other users found this report page using the following search terms: stem cells stem cell cord blood banking market worldwide cells markets development

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.